BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. It was identified in the 1990s by researchers studying the stomach's mucosal-protective mechanisms [1]. The peptide attracted early interest because of its apparent stability in gastric acid and its effects on healing in rodent models. Today it is widely discussed in recovery, biohacking, and sports communities for supposed tendon, gut, and soft-tissue repair properties.

The scientific reality is that the evidence base for BPC-157 is almost entirely preclinical — studies in cells and rats, not humans. No peer-reviewed randomized controlled trial has been completed in human subjects for any indication. In 2023-2024, the FDA placed BPC-157 in a category of bulk substances not eligible for use in compounded medications, effectively ending its availability from licensed US compounding pharmacies. It currently circulates primarily as an unregulated research chemical.

This page summarizes what the published literature actually shows, with every claim grounded in verified, peer-reviewed sources. Claims that appear only in animal research are explicitly labeled as preclinical. Readers should treat enthusiasm from online recovery communities as anecdote, not evidence.

In preclinical models, BPC-157 is proposed to act through modulation of the nitric oxide (NO) system and promotion of angiogenesis — the growth of new blood vessels into injured tissue [4]. It appears to interact with vascular endothelial growth factor (VEGF) pathways and to influence nitric oxide synthase activity, which may partly explain the wound-healing signals seen in rats. In the gastrointestinal tract, BPC-157 has been studied for its ability to protect the intestinal mucosa against injury from NSAIDs and other stressors by stabilizing mucosal barrier integrity and reducing local inflammation [2] [3].

For musculoskeletal applications — the most commercially promoted use — preclinical data suggest BPC-157 may accelerate fibroblast proliferation and tendon-to-bone remodeling in rat injury models [5]. The precise molecular pathway remains incompletely characterized, and the gap between rodent pharmacology and human therapeutic effect is large and unvalidated [6].

The BPC-157 evidence base is overwhelmingly preclinical. The published literature originates largely from a single research group at the University of Zagreb led by Predrag Sikiric, which has conducted extensive rat-model studies over three decades covering gastric mucosal protection [1] [2], tendon and ligament healing [5], and vascular biology [4]. These studies are internally consistent and mechanistically suggestive, but they are animal data — not human clinical evidence.

A 2026 translational review in Pharmaceutics by Mateescu et al. explicitly characterizes BPC-157 as an 'investigational peptide therapeutic' and identifies the complete absence of completed Phase I or Phase II human clinical trials as a fundamental barrier to clinical translation [6]. The review catalogs formulation challenges and biopharmaceutical uncertainties that further complicate the path to human studies. In plain terms: no human trial has been completed and published.

An independent 2026 review in Sports Medicine by Mendias and Awan evaluated the evidence for approved and unapproved peptide therapies in musculoskeletal injury and athletic performance. BPC-157 was among the unapproved peptides reviewed, and the authors concluded that the human clinical evidence is insufficient to support recommendations for its use in patients or athletes [7].

Evidence grade: C (preclinical only). Online claims of BPC-157's effectiveness for tendon repair, gut healing, or recovery in humans are extrapolations from animal data. The failure to conduct or complete human trials over three-plus decades of preclinical work is itself informative about the translational challenges involved.

No human dose has been established through clinical trials because no clinical trials in humans have been completed. Preclinical rodent studies have used approximate doses of 2 to 10 mcg/kg body weight administered subcutaneously or intragastrically. In the unregulated research-chemical market, providers and online sources commonly cite doses of 200 to 500 mcg per day administered by subcutaneous injection, or oral capsules of similar dose — but these parameters have no validated human pharmacokinetic or pharmacodynamic basis.

Oral formulations are widely available as research chemicals. Proponents argue that BPC-157 retains stability in gastric acid, which may support some oral bioavailability, though absorption data in humans do not exist. Because the FDA restricted BPC-157 from compounding in 2023-2024, it is no longer legally available from licensed US pharmacies and is sold primarily as an unlicensed research chemical not intended for human consumption.

The long-term safety profile of BPC-157 in humans is unknown. Preclinical rat studies have not identified frank organ toxicity at doses studied, but rodent safety data are not a reliable surrogate for human safety for complex peptides. The 2026 Mendias and Awan review noted that unapproved peptides including BPC-157 carry inherent risks from unregulated manufacturing, unknown purity, and the complete absence of pharmacovigilance data [7]. Products purchased as research chemicals online may contain incorrect doses, impurities, or different peptide sequences than labeled.

Regulatory context: the FDA Pharmacy Compounding Advisory Committee determined in 2023-2024 that BPC-157 does not meet the criteria for inclusion on the list of bulk drug substances that may be used in compounded preparations under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. BPC-157 is not FDA-approved for any human medical indication. Use outside of an IRB-approved clinical trial is unregulated and carries risks that cannot be quantified given the absence of human safety data.